Is Egrifta (Tesamorelin) Legal in Louisiana? How to Access It Legally

HealthRX.com

Egrifta is FDA-approved, but Louisiana rules are not covered here

Print or save as PDF

See the public record for Tesamorelin

  • FDA status / Approved prescription drug, BLA 022505, first approved November 10, 2010 [1]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy only [2]
  • Current products / Egrifta SV 2 mg vial (1.4 mg daily) and Egrifta WR 11.6 mg vial (1.28 mg daily) [2][3]
  • Route / Once-daily subcutaneous injection into the abdomen [2][3]
  • Compounding / No FDA category-based statement; not among the six peptides in the HHS draft policy [4][5][6][7][8]
  • Sport / Named on WADA's Prohibited List, prohibited at all times [9][10]

What is Egrifta's federal status?

FDA lists Egrifta (tesamorelin acetate) as a prescription product under application BLA 022505, originally approved November 10, 2010 [1]. The current labels are Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial; both are dated July 29, 2026, and both are given as once-daily subcutaneous injections [2][3]. Tesamorelin is a peptide, a synthetic analog of human growth hormone-releasing factor, not growth hormone itself [2].

Questions worth asking

Choose the questions you want to keep

What the approval covers

There is one approved use: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [2]. The label states that long-term cardiovascular safety has not been established, that the risk and benefit of continuing should be weighed in patients who have not had a reduction in visceral adipose tissue, and that it is not indicated for weight loss management because its effect on weight is neutral [2]. The label also states there are no data to support improved compliance with antiretroviral therapy [2].

The labels contraindicate tesamorelin in pregnancy, active malignancy, disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), and known hypersensitivity to tesamorelin or its excipients [2][3].

Can tesamorelin be compounded?

FDA has made no category-based statement about compounding tesamorelin. It does not appear on FDA's page of bulk substances that may present significant safety risks when compounded (content dated 04/22/2026) [4], it is in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) [5] or its list for outsourcing facilities (updated March 21, 2025) [6], and it is not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding filed October 28, 2026: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [7][8].

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8].

Doses and monitoring on the labels

Egrifta SV is labeled as 1.4 mg (0.35 mL of the reconstituted solution) once daily, while Egrifta WR is labeled as 1.28 mg (0.16 mL) once daily, both injected into the abdomen. The labels say the two products differ in dose, vial number, reconstitution and storage, and are not substitutable [2][3].

The label says to monitor IGF-1 during therapy and to evaluate glucose before and during treatment [2]. In the trials, among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated 52 weeks, 34% and 23% [2]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26 (hazard ratio about 3.3, 95% CI 1.4 to 9.6) [2].

Sport: WADA prohibits it

WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone-releasing factors and their analogues, prohibited at all times, in and out of competition [9]. It is on the 2026 List, in force since January 1, 2026, and stays on the 2027 List [9][10].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what is the one approved use of Egrifta (tesamorelin)?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is Egrifta legal in Louisiana?
Egrifta is an FDA-approved prescription drug under BLA 022505, first approved November 10, 2010, for excess abdominal fat in HIV-infected adults with lipodystrophy [1][2]. Louisiana's own prescribing, pharmacy-licensing and telehealth requirements are not addressed on this page.
Can a pharmacy compound tesamorelin?
FDA has made no category-based statement about compounding tesamorelin. It is not on FDA's significant-safety-risk page and is in no category of FDA's lists for state-licensed pharmacies, physicians or outsourcing facilities [4][5][6]. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing [8].
What dose does the label recommend?
Egrifta SV is labeled as 1.4 mg subcutaneously into the abdomen once daily; Egrifta WR is labeled as 1.28 mg once daily. The labels state the two products are not substitutable [2][3].
Is tesamorelin approved for weight loss?
No. The approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the label says it is not indicated for weight loss management because its effect on weight is neutral [2].
Is tesamorelin allowed in sport?
WADA names tesamorelin in S2.2.4 of its Prohibited List and prohibits it at all times, in and out of competition. It appears on both the 2026 and the 2027 List [9][10].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Has Tesamorelin been approved by the FDA?

Yes. FDA lists Egrifta (tesamorelin acetate) as a prescription product under application BLA 022505, originally approved November 10, 2010. Its one approved use is reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Was Egrifta discontinued?

No discontinuation is reported. FDA lists Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial) as current products, with both labels dated July 29, 2026, and both given as once-daily subcutaneous injections.

Which peptides are now legal?

No general list of legal peptides is given. Six peptides are named in HHS's draft enforcement-discretion policy for compounding: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. Tesamorelin is not one of them.

Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. Official web page.
  8. Official web page.
  9. World Anti-Doping Agency.
  10. World Anti-Doping Agency.
Evidence overview for Is Egrifta (Tesamorelin) Legal in Louisiana? How to Access It Legally